Your browser is no longer supported. Please, upgrade your browser.
Settings
ABT Abbott Laboratories daily Stock Chart
ABT [NYSE]
Abbott Laboratories
IndexS&P 500 P/E57.71 EPS (ttm)1.88 Insider Own0.30% Shs Outstand1.77B Perf Week-0.71%
Market Cap190.12B Forward P/E24.68 EPS next Y4.40 Insider Trans-4.58% Shs Float1.76B Perf Month3.22%
Income3.35B PEG4.35 EPS next Q1.36 Inst Own75.50% Short Float0.67% Perf Quarter1.82%
Sales32.22B P/S5.90 EPS this Y45.20% Inst Trans0.18% Short Ratio2.38 Perf Half Y18.70%
Book/sh17.69 P/B6.13 EPS next Y23.69% ROA5.00% Target Price119.94 Perf Year28.38%
Cash/sh2.70 P/C40.19 EPS next 5Y13.28% ROE11.00% 52W Range61.61 - 115.14 Perf YTD24.90%
Dividend1.44 P/FCF90.53 EPS past 5Y12.40% ROI8.20% 52W High-6.10% Beta0.81
Dividend %1.33% Quick Ratio1.20 Sales past 5Y9.50% Gross Margin56.80% 52W Low75.49% ATR2.53
Employees107000 Current Ratio1.70 Sales Q/Q9.60% Oper. Margin13.50% RSI (14)46.12 Volatility1.87% 2.33%
OptionableYes Debt/Eq0.59 EPS Q/Q28.10% Profit Margin10.50% Rel Volume0.46 Prev Close108.49
ShortableYes LT Debt/Eq0.58 EarningsOct 21 BMO Payout73.30% Avg Volume4.98M Price108.12
Recom1.90 SMA20-2.26% SMA50-0.33% SMA20012.44% Volume1,566,324 Change-0.34%
Sep-11-20Initiated Wolfe Research Outperform $124
Jun-01-20Downgrade Goldman Neutral → Sell $84
Mar-05-20Initiated Citigroup Buy $96
Feb-13-20Initiated Goldman Neutral $96
Feb-06-20Resumed BTIG Research Neutral
Jan-02-20Downgrade Guggenheim Buy → Neutral
Jun-13-19Reiterated BofA/Merrill Buy $81 → $90
Feb-07-19Reiterated BofA/Merrill Buy $73 → $81
Jan-02-19Downgrade Citigroup Neutral → Sell
Nov-30-18Upgrade Goldman Neutral → Buy
Oct-16-18Initiated Barclays Overweight $80
Jun-27-18Initiated Bernstein Outperform $73
Jan-30-18Reiterated Citigroup Neutral $59 → $64
Jan-25-18Upgrade William Blair Mkt Perform → Outperform
Jan-25-18Reiterated Stifel Buy $63 → $71
Jan-03-18Initiated Evercore ISI Outperform
Jan-02-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-02-18Upgrade JP Morgan Neutral → Overweight
Oct-19-17Reiterated Stifel Buy $58 → $63
Oct-19-17Reiterated RBC Capital Mkts Outperform $55 → $60
Dec-02-20 08:00AM  
08:00AM  
07:15AM  
Dec-01-20 09:56AM  
Nov-30-20 02:09PM  
Nov-27-20 01:24PM  
Nov-26-20 05:04PM  
Nov-23-20 10:50AM  
Nov-22-20 01:03AM  
Nov-21-20 06:09AM  
Nov-20-20 11:30AM  
Nov-18-20 09:00AM  
01:29AM  
Nov-17-20 09:00AM  
08:39AM  
Nov-16-20 11:56AM  
10:20AM  
Nov-15-20 09:51PM  
Nov-14-20 09:08AM  
08:00AM  
07:12AM  
Nov-13-20 12:19PM  
07:30AM  
Nov-12-20 08:46AM  
Nov-11-20 08:11AM  
Nov-10-20 09:58AM  
09:00AM  
06:05AM  
Nov-07-20 06:50AM  
06:06AM  
Nov-06-20 06:04AM  
Nov-05-20 01:31PM  
Nov-03-20 11:35AM  
11:21AM  
Nov-01-20 06:45AM  
Oct-31-20 07:00AM  
07:00AM  
Oct-30-20 09:00AM  
07:55AM  
Oct-29-20 08:18PM  
07:04AM  
06:50AM  
Oct-27-20 10:17AM  
06:45AM  
Oct-26-20 08:00AM  
Oct-25-20 06:10AM  
Oct-23-20 12:20PM  
11:36AM  
11:07AM  
09:25AM  
09:03AM  
06:14AM  
06:12AM  
Oct-22-20 01:19PM  
09:44AM  
06:08AM  
Oct-21-20 04:15PM  
02:08PM  
01:21PM  
11:15AM  
10:25AM  
10:21AM  
10:19AM  
09:51AM  
09:01AM  
08:54AM  
08:45AM  
07:52AM  
07:45AM  
07:42AM  
07:30AM  
Oct-20-20 01:05PM  
10:16AM  
08:32AM  
Oct-19-20 05:21PM  
03:56PM  
10:34AM  
07:15AM  
Oct-18-20 09:30AM  
06:31AM  
06:14AM  
Oct-17-20 06:09AM  
04:53AM  
01:08AM  
Oct-16-20 07:48PM  
09:53AM  
Oct-15-20 10:15AM  
06:24AM  
Oct-14-20 05:45PM  
12:30PM  
Oct-13-20 12:10PM  
10:33AM  
09:55AM  
08:39AM  
Oct-12-20 12:00PM  
12:00PM  
11:30AM  
10:11AM  
09:45AM  
09:00AM  
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Meniere's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OSBORN WILLIAM ADirectorNov 24Option Exercise43.6421,448935,99179,745Nov 25 05:41 PM
Funck Robert EExecutive Vice President & CFOOct 26Option Exercise38.4083,3333,199,987265,550Oct 28 06:33 PM
Funck Robert EExecutive Vice President & CFOOct 26Sale108.8383,3339,068,955182,217Oct 28 06:33 PM
Wainer Andrea FExecutive Vice PresidentSep 30Option Exercise38.4030,0001,152,00074,080Oct 01 05:50 PM
Wainer Andrea FExecutive Vice PresidentSep 30Sale107.0130,0003,210,36044,080Oct 01 05:50 PM
Wainer Andrea FExecutive Vice PresidentSep 23Sale102.473,650374,03144,080Sep 25 05:06 PM
WOODGRIFT RANDEL WILLIAMSenior Vice PresidentSep 11Sale105.282,500263,20046,267Sep 15 06:14 PM
Ginascol John FExecutive Vice PresidentSep 01Option Exercise43.1672,0983,111,584136,775Sep 03 06:33 PM
BIRD ROGERSenior Vice PresidentSep 01Sale108.736,290683,92956,630Sep 03 05:52 PM
CAPEK JOHN MExecutive Vice PresidentAug 27Option Exercise27.0352,3001,413,857369,100Aug 31 06:27 PM
Salvadori Daniel Gesua SiveExecutive Vice PresidentAug 27Option Exercise47.0042,4791,996,513144,912Aug 31 06:28 PM
Salvadori Daniel Gesua SiveExecutive Vice PresidentAug 27Sale111.8642,4794,751,701102,433Aug 31 06:28 PM
CAPEK JOHN MExecutive Vice PresidentAug 27Sale111.8652,3005,850,278316,800Aug 31 06:27 PM
NOVAKOVIC PHEBE NDirectorJul 23Option Exercise25.053,73993,67732,046Jul 27 05:06 PM
NOVAKOVIC PHEBE NDirectorJul 23Sale100.7893394,02631,113Jul 27 05:06 PM
AUSTIN ROXANNE SDirectorJul 22Sale99.806,844683,03840,043Jul 23 05:07 PM
PEDERSON MICHAEL JSenior Vice PresidentJul 21Option Exercise0.0023,008096,899Jul 23 05:04 PM
PEDERSON MICHAEL JSenior Vice PresidentJul 21Sale98.0023,0082,254,78473,891Jul 23 05:04 PM
Earnhardt Lisa DExecutive Vice PresidentJun 10Sale90.8487279,21672,074Jun 12 05:07 PM
LANE ANDREW HExecutive Vice PresidentMay 05Option Exercise43.8280,0003,505,314145,822May 07 05:02 PM
LANE ANDREW HExecutive Vice PresidentMay 05Sale92.0080,0007,360,10465,822May 07 05:02 PM
WOODGRIFT RANDEL WILLIAMSenior Vice PresidentApr 28Sale93.183,724347,01248,767Apr 30 06:34 PM
Funck Robert EExecutive Vice President & CFOApr 21Option Exercise36.4236,7001,336,638206,072Apr 23 09:27 PM
Contreras JaimeSenior Vice PresidentApr 21Option Exercise57.12108,4126,192,995145,431Apr 23 09:26 PM
CAPEK JOHN MExecutive Vice PresidentApr 21Option Exercise22.3950,1001,121,834366,900Apr 23 09:34 PM
Ginascol John FExecutive Vice PresidentApr 21Option Exercise38.4063,2002,426,880129,645Apr 23 09:41 PM
Ginascol John FExecutive Vice PresidentApr 21Sale96.0063,2006,067,05166,445Apr 23 09:41 PM
CAPEK JOHN MExecutive Vice PresidentApr 21Sale95.8750,1004,803,326316,800Apr 23 09:34 PM
Scoggins Christopher JSenior Vice PresidentApr 21Sale96.1041439,78539,706Apr 23 09:28 PM
Boudreau Philip PVice PresidentMar 13Sale82.0010,600869,20022,463Mar 16 06:47 PM
Watkin JaredSenior Vice PresidentMar 06Sale82.008,248676,33668,696Mar 10 05:06 PM
Funck Robert EExecutive Vice President & CFOMar 02Sale77.891,356105,619169,372Mar 03 05:28 PM
WOODGRIFT RANDEL WILLIAMSenior Vice PresidentMar 02Sale77.891,420110,60453,859Mar 03 05:27 PM
BIRD ROGERSenior Vice PresidentMar 02Sale77.8966651,87562,920Mar 03 05:23 PM
DALE MICHAEL DSenior Vice PresidentMar 02Sale77.8978761,29934,763Mar 03 05:21 PM
Ginascol John FExecutive Vice PresidentMar 02Sale77.636,606512,80566,445Mar 03 05:20 PM
Contreras JaimeSenior Vice PresidentMar 02Sale77.892,001155,85837,019Mar 03 05:19 PM
Watkin JaredSenior Vice PresidentMar 02Sale77.891,761137,16476,944Mar 03 05:19 PM
ALLEN HUBERT LExecutive Vice PresidentMar 02Sale77.891,20894,091151,896Mar 03 05:16 PM
Scoggins Christopher JSenior Vice PresidentMar 02Sale77.891,24096,58441,168Mar 03 05:15 PM
Salvadori Daniel Gesua SiveExecutive Vice PresidentMar 02Sale77.8999977,812103,493Mar 03 05:16 PM
BRYNELSEN CHARLESSenior Vice PresidentMar 02Sale77.891,781138,72245,460Mar 03 05:13 PM
Wainer Andrea FExecutive Vice PresidentMar 02Sale77.891,429111,30549,498Mar 03 05:10 PM
Moreland Mary KExecutive Vice PresidentFeb 25Sale84.9340033,97266,131Feb 25 05:29 PM
Moreland Mary KExecutive Vice PresidentFeb 19Sale88.971,01990,66052,985Feb 19 05:53 PM
DALE MICHAEL DSenior Vice PresidentFeb 19Sale88.9739635,23223,947Feb 19 05:53 PM
Wainer Andrea FExecutive Vice PresidentFeb 07Sale88.611,12099,24540,140Feb 11 06:10 PM
YOOR BRIAN BExecutive Vice President & CFOJan 28Option Exercise45.33509,85023,110,674624,231Jan 30 05:23 PM
YOOR BRIAN BExecutive Vice President & CFOJan 28Sale89.73509,85045,747,209114,381Jan 30 05:23 PM
MANNING JOSEPH JSenior Vice PresidentJan 27Option Exercise38.4037,5001,440,00088,032Jan 29 05:06 PM
MANNING JOSEPH JSenior Vice PresidentJan 27Sale89.5837,5003,359,41150,534Jan 29 05:06 PM